Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus

D Ferguson, BN Finck - Nature Reviews Endocrinology, 2021 - nature.com
Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease
in the world, yet there are still no approved pharmacological therapies to prevent or treat this …

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020

K Tokushige, K Ikejima, M Ono, Y Eguchi… - Journal of …, 2021 - Springer
Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only
in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic …

Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics

SA Polyzos, J Kountouras, CS Mantzoros - Metabolism, 2019 - Elsevier
The obesity epidemic is closely associated with the rising prevalence and severity of
nonalcoholic fatty liver disease (NAFLD): obesity has been linked not only with simple …

[HTML][HTML] From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options

A Gastaldelli, K Cusi - JHEP reports, 2019 - Elsevier
The worldwide prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to have
reached 25% or more in adults. NAFLD is prevalent in obese individuals, but may also affect …

Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management

T Marjot, A Moolla, JF Cobbold, L Hodson… - Endocrine …, 2020 - academic.oup.com
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of disease, extending from simple
steatosis to inflammation and fibrosis with a significant risk for the development of cirrhosis. It …

Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications

AJ Scheen - Diabetes & metabolism, 2019 - Elsevier
Patients with type 2 diabetes mellitus (T2DM) are exposed to non-alcoholic fatty liver
disease (NAFLD), a comorbidity associated with cardiovascular disease and chronic kidney …

Anti-obesity medications for the management of nonalcoholic fatty liver disease

SA Polyzos, DG Goulis, O Giouleme… - Current Obesity …, 2022 - Springer
Abstract Purpose of Review Obesity is closely associated with nonalcoholic fatty liver
disease (NAFLD), a highly prevalent disease without any approved medication. The aim of …

Current therapeutical approaches targeting lipid metabolism in NAFLD

M Vitulo, E Gnodi, G Rosini, R Meneveri… - International Journal of …, 2023 - mdpi.com
Nonalcoholic fatty liver disease (NAFLD, including nonalcoholic fatty liver (NAFL) and
nonalcoholic steatohepatitis (NASH)) is a high-prevalence disorder, affecting about 1 billion …

Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: a real‐world data analysis

S Colosimo, F Ravaioli, ML Petroni, L Brodosi… - Liver …, 2021 - Wiley Online Library
Abstract Background & Aims There is intense research for drugs able to reduce disease
progression in nonalcoholic fatty liver disease. We aimed to test the impact of novel …

The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review

M Zachou, P Flevari, N Nasiri-Ansari… - European Journal of …, 2024 - Springer
Purpose Non-alcoholic fatty liver disease (NAFLD) has become a leading cause of liver
disease, affecting 30% of the global population. NAFLD prevalence is particularly high in …